- $525.08m
- $228.05m
- $0.04m
Altimmune falls after Goldman resumes coverage with "sell", citing competition
Altimmune set for worst day ever after underwhelming data for liver disease drug
Altimmune slumps after mid-stage data for liver disease drug
Altimmune's weight-loss drug meets main goal in fatty liver disease trial (updated)
Altimmune's weight-loss drug meets main goal in fatty liver disease trial
Brief: Altimmune Announces Positive Topline Results From The Impact Phase 2B Trial Of Pemvidutide
Factbox: Fat, not muscle: Drugmakers in race for next weight-loss breakthrough
Brief: Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Altimmune Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Altimmune Secures Up To $100 Mln In Credit Facility From Hercules Capital
Brief: Altimmune Q1 Net Income USD -19.575 Million
Altimmune Inc expected to post a loss of 36 cents a share - Earnings Preview
Altimmune Inc expected to post a loss of 37 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-StoneX, US automakers, Johnson & Johnson
U.S. STOCKS ON THE MOVE-Intel, Orla Mining, Biogen
U.S. STOCKS ON THE MOVE-Pfizer, ConocoPhillips, NextDecade
U.S. STOCKS ON THE MOVE-Goldman Sachs, Pfizer, Best Buy
Obesity drugmakers rise after Pfizer ends development of weight-loss pill